Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: bioengineering

Printing Life: 3D Bio-Printed Organs

Explores the groundbreaking world of 3D bioprinting in regenerative medicine, where custom organs printed layer-by-layer from human cells are transforming transplantation. In this video, we uncover the latest advances in bioprinting technology, from biocompatible bioinks to vascularized tissue scaffolds that mimic natural organ architecture.

Dive into the science behind printing life as we showcase flagship projects: a beating mini heart engineered with human cardiomyocytes; 3D-printed liver organoids that perform metabolic functions; and personalized kidney scaffolds seeded with patient-derived stem cells. Learn how bio-printed skin grafts with integrated blood vessels accelerate wound healing and reduce scarring and discover innovations in printing complex structures like pancreas and lung tissue.

We break down key techniques—extrusion-based bioprinting, stereolithographic printing, and sacrificial ink methods—that enable high-resolution, cell-friendly constructs. Our experts explain challenges in tissue vascularization, bioink formulation, and regulatory pathways for clinical use. Gain insights into clinical trials driving the future of organ transplants without donor shortages.

Whether you’re a biotech researcher or tech enthusiast, this video offers insights and case studies. Don’t miss this cutting-edge guide to 3D bio-printed organs and tissue engineering.

#techforgood #futureofmedicine #aiinhealthcare #medicalai #bioprinting #tissueengineering #explainervideo #scienceexplained

UNM Researchers Receive Funding to Launch Clinical Trial of a New Alzheimer’s Vaccine

University of New Mexico researchers have received funding to launch an early-stage clinical trial of a vaccine engineered to clear pathological tau protein from the brains of patients suffering from Alzheimer’s dementia.

The Phase 1a/1b trial, supported in part by a $1 million grant from the Alzheimer’s Association’s Part the Cloud initiative, will test the novel vaccine, which was developed by UNM School of Medicine scientists, said Kiran Bhaskar, PhD, professor in the Departments of Molecular Genetics & Microbiology and Neurology.

“The primary endpoint of this study is safety and tolerability,” he said. “Can these subjects take these vaccinations without any anticipated side effects or adverse events? The second endpoint is the immunogenicity – can they make antibodies to tau?”

Sc: What research can be furthered?

What has not yet been tried? These are the questions that Inserm research director Nicolas L’Heureux has asked himself every day for a long time, « like a game ». Which means that from very early on he had the idea of pushing the limits of vascular tissue engineering – a field in which he had begun working when doing his M.Sc. « When performing a cardiac or other type of bypass, preference is given to using the patient’s own vessels that are taken from one place and transplanted into another, more critical, one. An autologous graft continues to remain the best solution, but it is a limited resource. » Diseases such as stroke, hyperlipidemia, and thrombosis, which have the particularity of being systemic – in which they attack all vessels to varying degrees –, as well as aging, weaken our vessels. And the earlier the need for surgery, the greater the likelihood of a second intervention. « A transplanted artery will withstand an average of ten years and a vein six to seven years. » Which just leaves synthetic grafts. https://www.inserm.fr/en/news/nicolas-lheureux-artificial-bl…iological/

See relevant content for m.

Gene editing offers transformative solution to saving endangered species

Gene editing technologies—such as those used in agriculture and de-extinction projects—can be repurposed to offer what an international team of scientists is calling a transformative solution for restoring genetic diversity and saving endangered species.

Researchers develop novel antibody-RNA therapy for resistant cancers

A specially engineered antibody that can accurately deliver RNA treatments into hard-to-reach and hard-to-treat tumors significantly improved survival and reduced tumor sizes in animal models, according to a study reported in Science Translational Medicine.

The study provides evidence that, once injected into the bloodstream, the antibody TMAB3, combined with a type of RNA that stimulates an innate immune reaction, can localize to tumors and penetrate and destroy stubborn diseased cells in pancreatic, brain, and .

“Delivery of RNA-based therapies to tumors has been a challenge. Our finding that TMAB3 can form antibody/RNA complexes capable of delivering RNA payloads to tumors provides a new approach to overcome this challenge,” says Peter Glazer, senior author and Robert E. Hunter Professor of Therapeutic Radiology and Genetics at Yale School of Medicine (YSM).

A Complete Human Genome Built from Scratch: This Unprecedented Scientific Feat Could Transform Everything We Know About Biology

IN A NUTSHELL 🌐 The SynHG project aims to synthesize a complete human genome, opening new horizons in biotechnology. ⚖️ Ethical considerations are central to the project, with a focus on responsible innovation and diverse cultural perspectives. 🧬 Initial steps involve creating a fully synthetic human chromosome, leveraging advances in synthetic biology and DNA chemistry.